Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.
The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.
Polyrizon (Nasdaq: PLRZ) ha annunciato risultati preclinici positivi per il suo PL-14 Allergy Blocker, dimostrando una somministrazione intranasale efficace in uno studio collaborativo con l'Universit脿 di Parma. Lo studio ha evidenziato una deposizione superiore al 60% del prodotto nel vestibolo nasale, il primo punto di contatto cruciale per gli allergeni trasportati dall'aria.
La ricerca conferma la validit脿 della piattaforma proprietaria Capture & Contain (C&C) dell'azienda, che supporta il suo meccanismo d'azione come barriera fisica contro gli allergeni. Il mercato globale degli allergeni, valutato 0,14 miliardi di dollari nel 2024, 猫 previsto crescere fino a 0,21 miliardi di dollari entro il 2033, con un tasso di crescita annuo composto del 4,4%. La societ脿 intende procedere verso le sperimentazioni cliniche dopo questi incoraggianti risultati preclinici.
Polyrizon (Nasdaq: PLRZ) ha anunciado resultados precl铆nicos positivos para su PL-14 Allergy Blocker, demostrando una administraci贸n intranasal exitosa en un estudio colaborativo con la Universidad de Parma. El estudio mostr贸 una deposici贸n superior al 60% del producto en el vest铆bulo nasal, el primer punto cr铆tico de contacto para los al茅rgenos en el aire.
La investigaci贸n valida la plataforma propietaria Capture & Contain (C&C) de la compa帽铆a, respaldando su mecanismo de acci贸n como una barrera f铆sica contra los al茅rgenos. El mercado global de bloqueadores de al茅rgenos, valorado en 0,14 mil millones de d贸lares en 2024, se proyecta que alcance 0,21 mil millones de d贸lares para 2033, creciendo a una tasa compuesta anual del 4,4%. La empresa planea avanzar hacia ensayos cl铆nicos tras estos alentadores resultados precl铆nicos.
韽措Μ霛检澊歃� (Nasdaq: PLRZ)鞚赌 PL-14 鞎岆爤毳搓赴 彀嫧鞝�鞐� 雽�頃� 旮嶌爼鞝侅澑 鞝勳瀯靸� 瓴瓣臣毳� 氚滍憸頄堨溂氅�, 韺岆ゴ毵� 雽�頃欔祼鞕�鞚� 瓿惦彊 鞐瓣惮鞐愳劀 牍勱皶 雮� 韴棳臧� 靹标车鞝侅瀯鞚� 鞛呾頄堨姷雼堧嫟. 鞐瓣惮 瓴瓣臣電� 瓿店赴 欷� 鞎岆爤毳搓矏瓿� 觳橃潓 鞝戩磯頃橂姅 欷戩殧頃� 攵�鞙勳澑 牍勱皶 鞛呹惮鞐� 60% 鞚挫儊鞚� 鞝滍拡 旃癌鞚� 氤挫棳欤检棃鞀惦媹雼�.
鞚� 鞐瓣惮電� 須岇偓鞚� 霃呾瀽鞝侅澑 Capture & Contain (C&C) 頂岆灚韽�鞚� 瓴�歃濏晿氅�, 鞎岆爤毳搓矏鞐� 雽�頃� 氍茧Μ鞝� 鞛ル步鞙茧靹滌潣 鞛戩毄 氅旍护雼堨鞚� 霋冯皼旃暕雼堧嫟. 2024雲� 1鞏� 4觳滊 雼煬搿� 韽夑皜霅� 鞝� 靹戈硠 鞎岆爤毳搓矏 彀嫧鞝� 鞁滌灔鞚赌 2033雲勱箤歆� 2鞏� 1觳滊 雼煬鞐� 鞚措ゼ 瓴冹溂搿� 鞓堨儊霅橂┌, 鞐绊弶攴� 靹膘灔毳犾澏� 4.4%鞛呺媹雼�. 須岇偓電� 鞚措煬頃� 瓿犽鞝侅澑 鞝勳瀯靸� 瓴瓣臣毳� 氚旐儠鞙茧 鞛勳儊 鞁滍棙 雼硠搿� 雮橃晞臧� 瓿勴殟鞛呺媹雼�.
Polyrizon (Nasdaq : PLRZ) a annonc茅 des r茅sultats pr茅cliniques positifs pour son PL-14 Allergy Blocker, d茅montrant une administration intranasale r茅ussie dans une 茅tude collaborative avec l'Universit茅 de Parme. L'茅tude a montr茅 une d茅position de plus de 60% du produit dans le vestibule nasal, le premier point de contact crucial pour les allerg猫nes a茅roport茅s.
La recherche valide la plateforme propri茅taire Capture & Contain (C&C) de l'entreprise, soutenant son m茅canisme d'action en tant que barri猫re physique contre les allerg猫nes. Le march茅 mondial des bloqueurs d'allerg猫nes, 茅valu茅 脿 0,14 milliard de dollars en 2024, devrait atteindre 0,21 milliard de dollars d'ici 2033, avec un taux de croissance annuel moyen de 4,4%. L'entreprise pr茅voit d'avancer vers des essais cliniques suite 脿 ces r茅sultats pr茅cliniques encourageants.
Polyrizon (Nasdaq: PLRZ) hat positive pr盲klinische Ergebnisse f眉r seinen PL-14 Allergy Blocker bekannt gegeben und in einer gemeinsamen Studie mit der Universit盲t Parma eine erfolgreiche intranasale Verabreichung nachgewiesen. Die Studie zeigte eine Deposition von 眉ber 60% des Produkts im Nasenvorhof, dem entscheidenden ersten Kontaktpunkt f眉r luftgetragene Allergene.
Die Forschung best盲tigt die firmeneigene Capture & Contain (C&C)-Plattform und unterst眉tzt deren Wirkmechanismus als physikalische Barriere gegen Allergene. Der globale Markt f眉r Allergenblocker, der im Jahr 2024 mit 0,14 Milliarden US-Dollar bewertet wird, soll bis 2033 auf 0,21 Milliarden US-Dollar anwachsen und mit einer j盲hrlichen Wachstumsrate von 4,4% wachsen. Das Unternehmen plant, nach diesen vielversprechenden pr盲klinischen Ergebnissen mit klinischen Studien fortzufahren.
- Achieved over 60% deposition in the nasal vestibule, demonstrating effective targeted delivery
- Product showed favorable sprayability and coverage for self-administration
- Addresses growing allergen blocker market projected to reach $0.21B by 2033
- Still in preclinical stage, requiring further validation and clinical trials
- Entering a competitive market with modest 4.4% CAGR growth rate
Insights
Polyrizon's PL-14 shows promising preclinical results with 60%+ nasal vestibule deposition, advancing its potential in the growing allergen blocker market.
Polyrizon's preclinical study results for its PL-14 Allergy Blocker represent a significant technical milestone in the company's development pipeline. The study demonstrated that PL-14 achieved over 60% deposition in the nasal vestibule, which is critical for the product's mechanism of action as a physical barrier against allergens.
The technical achievement here is noteworthy because targeted delivery to the nasal vestibule鈥攖he first area of contact for airborne allergens鈥攊s precisely what's needed for the product's "Capture & Contain" approach to work effectively. By forming a protective hydrogel barrier at the entry point of allergens, PL-14 aims to prevent allergic reactions before they begin, rather than treating symptoms after they've started.
From a market perspective, Polyrizon is positioning itself in the allergen blocker market valued at
The collaboration with the University of Parma and specifically Professor Fabio Sonvico adds credibility to these findings. The use of a validated silicone-based human nasal cast model with fluorescein-labeled imaging represents a standard approach for evaluating intranasal drug delivery before moving to human trials.
This announcement indicates progression toward clinical trials, though the company remains in the preclinical validation phase. For investors, this represents forward momentum in Polyrizon's development pipeline, though considerable development steps remain before commercialization could be achieved.
Ra鈥檃nana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (鈥淧olyrizon鈥� or the 鈥淐ompany鈥�), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary聽Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule鈥攖he key anatomical site for early allergen contact鈥攔einforcing the product鈥檚 potential as a barrier-forming treatment for allergic rhinitis.
The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon鈥檚 Scientific Advisory Board. Using a validated silicone-based human nasal cast and fluorescein-labeled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.
The results revealed that the PL-14 formulation achieved over
鈥淲e believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward,鈥� said Tomer Izraeli, CEO of Polyrizon. 鈥淭hese results support the core principle behind our blocker products鈥攖o form a protective layer at the point of allergen entry and prevent the initiation of allergic reactions.鈥�
According to , the global allergen blocker market size was valued at USD 0.14 billion in 2024 and is expected to reach USD 0.21 billion by 2033, exhibiting a CAGR of
PL-14鈥檚 performance in this nasal cast model highlights its potential to become a frontline preventive treatment for allergic rhinitis. The hydrogel formulation also maintained favorable sprayability and coverage under standard administration angles, demonstrating its practicality for self-administration.
Polyrizon plans to continue preclinical validation and advance toward clinical trials as part of the development path for the C&C platform.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon鈥檚 proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a 鈥渂iological mask鈥� with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target 鈩�, or T&T. For more information, please visit .
Forward Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates鈥� and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the PL-14 Allergy Blocker鈥檚 potential as a barrier-forming and frontline preventive treatment for allergic rhinitis, the expected growth of the global allergen blocker market and the Company鈥檚 continued preclinical validation and advancement toward clinical trials as part of the development path for the C&C platform. Forward-looking statements are not historical facts, and are based upon management鈥檚 current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management鈥檚 expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company鈥檚 reports filed from time to time with the Securities and Exchange Commission (鈥淪EC鈥�), including, but not limited to, the risks detailed in the Company鈥檚 annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
What were the key findings of Polyrizon's (PLRZ) PL-14 Allergy Blocker study?
How does Polyrizon's PL-14 Allergy Blocker work?
What is the market potential for Polyrizon's allergy blocker?
What are the next steps for Polyrizon's PL-14 development?
Who conducted the study for Polyrizon's PL-14 Allergy Blocker?
